Login / Signup
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
Albert Grinshpun
Sara M Tolaney
Harold J Burstein
Rinath M Jeselsohn
Erica L Mayer
Published in:
NPJ breast cancer (2023)
Keyphrases
</>
metastatic breast cancer
cell cycle
cell proliferation